Skip to main content

Health condition

Metachromatic leukodystrophy, and why timing decides everything.

A rare inherited disorder that damages the nervous system's myelin. Gene therapy and transplant can halt it - but only before real damage sets in.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE, NHS England commissioning policy and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including NHS-commissioned gene therapy and transplant pathways.

Key facts

MLD at a glance.

The essentials, in plain English - what it is, the three types, and how it's approached in the UK today.

  • What it is

    A rare, inherited, autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme arylsulfatase A.

  • The mechanism

    ARSA gene mutations lead to sulfatide build-up that damages the myelin sheath, causing progressive demyelination in the nervous system.

  • Three types

    Late infantile, juvenile and adult forms - classified by age of onset, which broadly predicts severity and speed of progression.

  • Most severe form

    Late infantile MLD, with onset before age two to three, is the most common presentation and progresses fastest.

  • A treatable window

    Gene therapy and stem cell transplant can halt progression, but only work if given before significant neurological damage occurs.

  • Family testing

    Genetic counselling and cascade testing for siblings are time-critical once one child in a family is diagnosed.

Why this guide matters

A rare disease where speed of diagnosis changes the outcome.

MLD is rare, but the arrival of gene therapy has genuinely changed what's possible. The three points below shape everything else on this page.

  • Regression is the warning sign

    Losing skills a child or adult already had - not simply being delayed - is the pattern that should prompt urgent specialist assessment.

  • The treatment window is narrow

    Gene therapy and stem cell transplant work best, and sometimes only, before significant neurological damage has occurred.

  • Family testing can be lifesaving

    Once one child is diagnosed, testing siblings quickly can identify a pre-symptomatic case still within the treatable window.

How the diagnosis is made

From first concern to a confirmed diagnosis.

The steps a UK specialist metabolic and neurology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Recognising

    Recognising regression

    Loss of previously acquired motor, speech or cognitive skills after normal early development is the classic trigger for assessment.

  2. 02

    Recognising

    Neurological examination

    Gait, tone, reflexes and developmental milestones are checked against what the child or adult could do before.

  3. 03

    Confirming

    Enzyme assay

    Arylsulfatase A activity is measured in leucocytes or fibroblasts - reduced or absent activity supports the diagnosis.

  4. 04

    Confirming

    Urine sulfatide testing

    Elevated urinary sulfatide levels add further supporting evidence alongside the enzyme assay.

  5. 05

    Confirming

    MRI brain

    A characteristic leukodystrophy pattern of white matter change is seen on specialist neuroradiology imaging.

  6. 06

    Confirming

    Nerve conduction studies

    Specialist neurophysiology often shows reduced conduction velocities, confirming peripheral nerve involvement.

  7. 07

    Confirming

    Genetic testing and MDT confirmation

    ARSA gene sequencing confirms the diagnosis and identifies carriers, guiding a specialist metabolic paediatrics, neurology and genetics team.

Typical timeline: investigations to a confirmed diagnosis within a few weeks, coordinated by a specialist metabolic team.

Symptoms

What MLD actually looks like.

Presentation depends heavily on age of onset - from infant regression to adult behavioural change. And the features that mean it's time to escalate.

  • Developmental regression

    Loss of skills already gained - walking, talking or fine motor control - after a period of apparently normal development, most typical of late infantile MLD.

  • Gait disturbance and weakness

    Unsteady walking, frequent falls and progressive limb weakness as demyelination advances.

  • Hypotonia to spasticity

    Early floppiness can give way to stiffness and spasticity as the disease progresses through the nervous system.

  • Cognitive decline

    Slowing thinking, memory difficulty and, in children, falling behind at school - often an early sign in juvenile and adult forms.

  • Behavioural and psychiatric change

    Personality change, poor concentration or new psychiatric symptoms are frequently the first clue in juvenile and adult-onset disease.

  • Peripheral neuropathy

    Tingling, numbness or weakness from nerve involvement outside the brain and spinal cord, confirmed on nerve conduction studies.

  • Vision and speech loss

    Progressive loss of vision and speech occurs as the disease advances, particularly in the late infantile form.

  • Red flag - rapid regression in infancy

    Sudden loss of milestones in a toddler after normal development needs urgent same-week paediatric neurology assessment.

Treatment

How MLD is treated in the UK.

NHS-commissioned gene therapy and transplant for early disease, alongside comprehensive supportive and palliative care for more advanced cases.

  • Gene therapy (Libmeldy)

    Atidarsagene autotemcel - an NHS-commissioned, NICE-approved ex vivo gene therapy for early-onset MLD, given before significant neurological damage in pre-symptomatic or early symptomatic disease.

  • Haematopoietic stem cell transplant

    Can halt progression when performed early, particularly in juvenile or adult forms, or pre-symptomatically in late infantile MLD identified through family screening.

  • Multidisciplinary supportive care

    Physiotherapy, occupational therapy and speech and language therapy to manage function, feeding difficulties and communication as the disease progresses.

  • Seizure and spasticity management

    Anti-epileptic medication and spasticity treatment to manage two of the more distressing features of advancing disease.

  • Nutritional support

    Feeding difficulties are common as MLD progresses - dietetic input and, where needed, feeding tube support maintain nutrition and comfort.

  • Palliative care input

    For advanced disease, particularly the late infantile form, given its progressive and ultimately life-limiting nature.

  • Family genetic counselling

    Cascade testing for siblings and reproductive counselling - especially urgent given the narrow window for gene therapy in pre-symptomatic cases.

  • Early identification pathways

    Given the narrow therapeutic window, early recognition and rapid referral are as important as the treatments themselves.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, NHS commissioning policy and specialist patient organisation resources, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your specialist metabolic or neurology team knows your family's situation and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST15).

  • NHS England. Clinical commissioning policy for haematopoietic stem cell transplantation in inherited metabolic disease.

  • Orphanet. Metachromatic leukodystrophy - clinical and genetic overview.

  • Metabolic Support UK. Patient and family information on metachromatic leukodystrophy.

Red flags

When MLD needs urgent attention.

Given how narrow the treatment window is, these are the situations where delay carries a real cost - and where urgent specialist input is needed.

  • Rapid regression in a toddler

    Sudden loss of walking, speech or previously acquired skills before age three needs urgent paediatric neurology assessment.

  • New seizures with regression

    Seizures appearing alongside developmental regression are a marker of advancing disease and need prompt specialist review.

  • Family history of MLD

    A sibling or relative already diagnosed makes urgent, pre-symptomatic testing of other children time-critical for gene therapy eligibility.

  • Rapid loss of vision or speech

    Progressive loss of these functions signals advancing demyelination and should prompt immediate specialist metabolic neurology input.

  • Missing the treatment window

    Gene therapy and transplant only work before significant neurological damage - any delay in referral can close this window permanently.

  • New psychiatric symptoms in a young adult

    Unexplained personality change, cognitive decline or psychiatric presentation in a young adult can be adult-onset MLD and warrants metabolic screening.

  • Feeding or breathing difficulty

    Advanced disease affecting swallowing or respiration needs urgent multidisciplinary and palliative care involvement.

Living with it

A rare disease, carried with the right team around you.

Four things that make the biggest difference for families - a coordinated specialist team, fast sibling testing, peer support and honest planning.

A quiet reminder

You are not expected to navigate this alone.

Specialist metabolic centres, genetic counsellors and patient charities exist precisely because MLD is rare and complex.

  1. 01 Team

    Build a specialist MDT early

    Metabolic paediatrics or neurology, genetics, physiotherapy and palliative care working together give the most consistent care.

  2. 02 Family

    Test siblings without delay

    Cascade genetic testing can identify pre-symptomatic siblings while gene therapy or transplant can still change the disease course.

  3. 03 Support

    Connect with Metabolic Support UK

    Peer and practical support from families who understand MLD makes a genuine difference alongside clinical care.

  4. 04 Planning

    Plan ahead, kindly

    Open conversations about goals of care, equipment needs and palliative support help families feel prepared rather than overwhelmed.

Frequently asked

Everything we get asked about MLD.

Quick answers on diagnosis, gene therapy, family testing and what to expect.

  • What is metachromatic leukodystrophy?

    A rare, inherited, autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme arylsulfatase A. This leads to sulfatide accumulation that damages the myelin sheath in the central and peripheral nervous systems, causing progressive demyelination.

  • What are the different types of MLD?

    MLD is classified by age of onset. Late infantile (before age two to three) is the most common and most severe. Juvenile MLD begins between three and sixteen years. Adult MLD begins after sixteen and generally progresses more slowly, though it remains ultimately disabling.

  • How is MLD diagnosed?

    Diagnosis combines an enzyme assay measuring arylsulfatase A activity in leucocytes or fibroblasts, urine sulfatide testing, MRI brain showing a characteristic leukodystrophy pattern, nerve conduction studies, and ARSA gene sequencing to confirm the diagnosis and identify carriers.

  • Is there a cure for MLD?

    Gene therapy (atidarsagene autotemcel, branded Libmeldy) and haematopoietic stem cell transplantation can halt progression when given early enough, particularly before significant symptoms develop. Neither reverses damage that has already occurred, which makes early diagnosis critical.

  • Why is early diagnosis so important in MLD?

    Gene therapy and transplant only work if performed before significant, irreversible neurological damage has occurred. This narrow therapeutic window means early identification, often through family screening after a sibling is diagnosed, is essential to accessing effective treatment.

  • Should other children in the family be tested?

    Yes. Once one child is diagnosed with MLD, cascade genetic testing of siblings is strongly recommended and time-critical, since a pre-symptomatic sibling may still be eligible for gene therapy or transplant before symptoms begin.

Related content

Keep reading.